Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Salarius Pharmaceuticals Inc SLRX

Healthcare Biotechnology
Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing treatments for parties with cancers in need of new treatment options. Its product portfolio includes seclidemstat, an oral novel small molecule inhibitor of the LSD1 enzyme and the Company's lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas, and... see more

Recent & Breaking News (NDAQ:SLRX)

Flex Pharma’s Phase 2 Trial with FLX-787 in Charcot-Marie-Tooth Endorsed by the Inherited Neuropathies Consortium

Business Wire June 2, 2017

Flex Pharma Presenting at Upcoming Investor Conferences in June 2017

Business Wire May 30, 2017

Flex Pharma Reports First Quarter 2017 Financial Results

Business Wire May 3, 2017

FDA Clears Flex Pharma's FLX-787 to Commence US Phase 2 Trial in ALS Under IND

Business Wire April 26, 2017

Flex Pharma Names William K. McVicar, Ph.D. as President, Research & Development

Business Wire April 5, 2017

Newly-Published Study Reinforces Efficacy Of HOTSHOT® In Preventing And Treating Muscle Cramps

PR Newswire March 23, 2017

Flex Pharma Reports Year End 2016 Financial Results

Business Wire March 8, 2017

Flex Pharma to Report Fourth Quarter and Full Year 2016 Results on March 8, 2017

Business Wire March 1, 2017

Champion Triathlete Finds Solution For Struggle With Muscle Cramps

PR Newswire February 15, 2017

Flex Pharma to Present at the BIO CEO & Investor Conference

Business Wire February 7, 2017

Flex Pharma Focuses on Phase 2 Clinical Programs in Severe Neurological Diseases

Business Wire January 24, 2017

Champion Pro Football Fullback Goes On The Offense Against Game-Changing Cramps

PR Newswire December 20, 2016

Flex Pharma to Present at the Piper Jaffray 28th Annual Healthcare Conference

Business Wire November 21, 2016

Flex Pharma to Present at the Jefferies 2016 Healthcare Conference

Business Wire November 9, 2016

Flex Pharma Reports Third Quarter 2016 Financial Results

Business Wire November 2, 2016

Flex Pharma to Report Third Quarter 2016 Results on November 2, 2016

Business Wire October 26, 2016

Mid-Afternoon Market Update: Lindsay Gains Following Q4 Results; Fluidigm Shares Drop

Benzinga.com  October 13, 2016

Mid-Day Market Update: Ocular Therapeutix Surges Following Collaboration Deal With Regeneron; Flex Pharma Shares Slide

Benzinga.com  October 13, 2016

Flex Pharma Provides FLX-787 Nocturnal Leg Cramp Regulatory and Clinical Update

Business Wire October 13, 2016

Flex Pharma Initiates Phase 2 Efficacy Study in Amyotrophic Lateral Sclerosis

Business Wire September 13, 2016